Metropolitan Life Insurance Company (MetLife)’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,773
| Closed | -$9.43K | – | 2359 |
|
|
2023
Q3 | $9.43K | Hold |
2,773
| – | – | ﹤0.01% | 2235 |
|
|
2023
Q2 | $20.4K | Buy |
2,773
+606
| +28% | +$5.62K | ﹤0.01% | 1917 |
|
|
2023
Q1 | $22.4K | Sell |
2,167
-854
| -28% | -$10.3K | ﹤0.01% | 1829 |
|
|
2022
Q4 | $35.7K | Hold |
3,021
| – | – | ﹤0.01% | 1686 |
|
|
2022
Q3 | $63.4K | Hold |
3,021
| – | – | ﹤0.01% | 1293 |
|
|
2022
Q2 | $93.8K | Hold |
3,021
| – | – | ﹤0.01% | 1087 |
|
|
2022
Q1 | $124K | Sell |
3,021
-10,076
| -77% | -$444K | ﹤0.01% | 1071 |
|
|
2021
Q4 | $569K | Sell |
13,097
-7,775
| -37% | -$352K | 0.01% | 1335 |
|
|
2021
Q3 | $1.05M | Buy |
20,872
+340
| +2% | +$20.6K | 0.02% | 912 |
|
|
2021
Q2 | $1.29M | Buy |
20,532
+858
| +4% | +$55.1K | 0.02% | 810 |
|
|
2021
Q1 | $1.83M | Sell |
19,674
-19
| -0.1% | -$1.95K | 0.03% | 561 |
|
|
2020
Q4 | $1.76M | Sell |
19,693
-714
| -3% | -$65.5K | 0.03% | 537 |
|
|
2020
Q3 | $2.11M | Buy |
20,407
+6,689
| +49% | +$721K | 0.04% | 397 |
|
|
2020
Q2 | $1.08M | Hold |
13,718
| – | – | 0.02% | 690 |
|
|
2020
Q1 | $794K | Sell |
13,718
-589
| -4% | -$33.9K | 0.02% | 799 |
|
|
2019
Q4 | $772K | Sell |
14,307
-342
| -2% | -$18.5K | 0.01% | 1061 |
|
|
2019
Q3 | $766K | Hold |
14,649
| – | – | 0.01% | 1017 |
|
|
2019
Q2 | $708K | Hold |
14,649
| – | – | 0.01% | 1093 |
|
|
2019
Q1 | $740K | Hold |
14,649
| – | – | 0.01% | 1054 |
|
|
2018
Q4 | $868K | Buy |
14,649
+164
| +1% | +$10.6K | 0.02% | 883 |
|
|
2018
Q3 | $954K | Hold |
14,485
| – | – | 0.02% | 966 |
|
|
2018
Q2 | $731K | Buy |
14,485
+3,696
| +34% | +$193K | 0.01% | 1086 |
|
|
2018
Q1 | $568K | Buy |
10,789
+215
| +2% | +$10.7K | 0.01% | 1191 |
|
|
2017
Q4 | $491K | Sell |
10,574
-12,706
| -55% | -$535K | 0.01% | 1304 |
|
|
2017
Q3 | $942K | Hold |
23,280
| – | – | 0.01% | 1289 |
|
|
2017
Q2 | $789K | Hold |
23,280
| – | – | 0.01% | 1379 |
|
|
2017
Q1 | $676K | Hold |
23,280
| – | – | ﹤0.01% | 1454 |
|
|
2016
Q4 | $765K | Hold |
23,280
| – | – | 0.01% | 1452 |
|
|
2016
Q3 | $734K | Hold |
23,280
| – | – | 0.01% | 1461 |
|
|
2016
Q2 | $655K | Buy |
23,280
+314
| +1% | +$12.3K | ﹤0.01% | 1528 |
|
|
2016
Q1 | $835K | Hold |
22,966
| – | – | 0.01% | 1264 |
|
|
2015
Q4 | $919K | Buy |
22,966
+2,307
| +11% | +$80.4K | 0.01% | 1228 |
|
|
2015
Q3 | $589K | Hold |
20,659
| – | – | ﹤0.01% | 1532 |
|
|
2015
Q2 | $681K | Sell |
20,659
-565
| -3% | -$17.5K | ﹤0.01% | 1545 |
|
|
2015
Q1 | $610K | Sell |
21,224
-1,554
| -7% | -$44.6K | ﹤0.01% | 1451 |
|
|
2014
Q4 | $620K | Buy |
22,778
+1,640
| +8% | +$39.1K | ﹤0.01% | 1616 |
|
|
2014
Q3 | $450K | Hold |
21,138
| – | – | ﹤0.01% | 1780 |
|
|
2014
Q2 | $475K | Hold |
21,138
| – | – | ﹤0.01% | 1862 |
|
|
2014
Q1 | $534K | Hold |
21,138
| – | – | ﹤0.01% | 1767 |
|
|
2013
Q4 | $486K | Sell |
21,138
-1,486
| -7% | -$31K | ﹤0.01% | 1827 |
|
|
2013
Q3 | $431K | Buy |
22,624
+1,486
| +7% | +$26.5K | ﹤0.01% | 1850 |
|
|
2013
Q2 | $305K | Buy |
+21,138
| New | +$306K | ﹤0.01% | 2030 |
|
Other funds holding EBS
Metropolitan Life Insurance Company (MetLife)'s EBS Position: Q4 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 2,773 shares — an estimated $9.43K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in EBS in Q2 2013 and held it in 42 quarters. The position peaked at $2.11M in Q3 2020. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 2,773 Emergent Biosolutions shares in Q4 2023, an estimated $9.43K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Emergent Biosolutions in Q2 2013 and held it in 42 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Emergent Biosolutions position peaked at $2.11M in Q3 2020.
- 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.